Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GD2 CAR T cells (UCL)
- Development stage
- Unknown
- Lead developer
- University College London
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
GD2 CAR T cells (UCL) is an autologous cell-based immunotherapy developed by University College London for the treatment of neuroblastoma. The therapy consists of a patient's own T cells that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the disialoganglioside GD2, a well-validated antigen highly expressed on neuroblastoma cells. This specific 'multi-modular' construct includes additional transgenes designed to enhance the cells' resistance to the immunosuppressive tumor microenvironment and improve their persistence and functional activity within the tumor. The therapy is currently being evaluated in the Phase I MAGNETO clinical trial for children and teenagers with relapsed or refractory neuroblastoma, following lymphodepletion chemotherapy.
- Other names
- Multi-modular GD2 CAR T cellsAutologous GD2 CAR T cellsGD2-targeting CAR T cellsGD-2-targeting CAR T cellsGD 2-targeting CAR T cells
02
Targets
GD2
Beyond the preview
Go deeper on GD2 CAR T cells (UCL).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GD2 CAR T cells (UCL).